Matrix Laboratories (Delisted) share news and announcements
BSE: 524794
Last traded ₹209.35 on 13 Aug 2009
Delisted on 21 Aug 2009.
Matrix Laboratories board meetings
17 filed, newest first.
Jul 2009
21 Jul · Board meeting
Meeting on 29 Jul 2009: “Unaudited Financial Results for the Qtr ended June 30, 2009”
Jun 2009
15 Jun · Board meeting
Inter-alia to consider and approve the Audited Financial Results of the Company for the Fourth Quarter and Year ended March 31, 2009.
Jan 2009
28 Jan · Board meeting
At the meeting of the Board of Directors of the Company, held on January 28, 2009 the Board has approved: (a) conversion of 1000 partly paid up equity shares of Rs.2/- each into fully paid up equity shares on account of receipt of calls in arrears. (b) forfeiture of 15500 partly paid up equity shares of Rs.2/- each, on account of non receipt of calls in arrears. The details of the forfeited shares shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.19 Jan · Board meeting
Inter alia to consider and approve the "Unaudited Financial Results" of the Company for the third quarter and nine months ended December 31, 2008.
Oct 2008
30 Oct · Board meeting
Board of Directors of the Company at its meeting held on October 29, 2008, the Board approved: 1) Conversion of 6718 partly paid up equity shares of Rs.2/- each into fully paid up equity shares on account of receipt of calls-in-arrears. 2) Issue of a Final Notice to the Shareholders holding 16500 partly paid up Equity Shares of Rs.2/- each, advising them to remit the calls-in-arrears along with the interest on or before December 02, 2008.21 Oct · Board meeting
Inter alia to consider and approve the "Unaudited Financial Results" of the Company for the second quarter and half-year ended September 30, 2008.
Jul 2008
18 Jul · Board meeting
Meeting on 29 Jul 2008: “Unaudited Financial Results for the Qtr ended June 30, 2008”
Jun 2008
20 Jun · Board meeting
Inter-alia to consider and approve the Audited Financial Results of the Company for the Fourth Quarter and Year ended March 31, 2008.
Jan 2008
17 Jan · Board meeting
Inter alia, to, consider and approve the "Unaudited Financial Results" of the Company for the third quarter and nine months ended December 31, 2007.
Oct 2007
22 Oct · Board meeting
Inter alia to, consider and approve the "Unaudited Financial Results' for the second quarter and half year ended September 30, 2007.
Jul 2007
17 Jul · Board meeting
Meeting on 25 Jul 2007: “Unaudited financial results for quarter ended June 30, 2007”
May 2007
15 May · Board meeting
Inter- alia to consider and approve the Audited Financial Results of the Company for the Fourth Quarter and Year ended March 31, 2007.
Feb 2007
1 Feb · Board meeting
January 31, 2007, that: "The Board of Directors of the Company at their meeting held on even date considered and approved the following items : Agreement dated January 31, 2007 with Mr. Rajiv Malik pursuant to which Mr. Malik will continue as the Managing Director and acting Chief Executive Officer of the Company on deputation from Mylan Laboratories Inc. (USA), for whom Mr. Malik serves as Head of Global Technical Operations. An abstract of the terms and conditions of Mr. Rajiv Malik's agreement with Matrix would be forwarded to the Members, as required under Section 302 of the Companies Act, 1956".
Jan 2007
31 Jan · Board meeting
Board Meeting of the Company scheduled to be held on January 30, 2007 for considering and approving the unaudited financial results for the quarter ended December 31, 2006 is adjourned for January 31, 2007.22 Jan · Board meeting
Meeting on 30 Jan 2007: “Unaudited Financial Results for the quarter ended Dec 31, 06”9 Jan · Board meeting
(ii) Resignation of Directors (iii) Appointment of Additional Director (iv) Reconstitution of Committees. The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.9 Jan · Board meeting
The Board of Directors of the Company at their meeting held today i.e. 8th January, 2007 :- i) Noted that the transactions under the Share Purchase Agreement (SPA) between MP Laboratories (Mauritius) Ltd, a wholly owned subsidiary of Mylan Laboratories Inc. U.S.A. ('Acquirers'), and Mr. Prasad Nimmagadda, Prasad Nimmagadda-HUF, G2 Corporate Services Limited, India Newbridge Investments Limited, India Newbridge Partners FDI Limited, India Newbridge Coinvestment Limited, Maxwell (Mauritius) Pte Limited and Spandana Foundation ('the Selling Shareholders'), entered into on 28th August 2006 have consummated and consequent upon the closing of the transactions, the Acquirers have acquired approximately 51.5% of the voting share capital of the Company, pursuant to the said SPA. Further, the Acquirers also completed acquisition of 20% of the fully diluted share capital through open offer. On completion of acquisition of shares under SPA and Open Offer, the Acquirers acquired an aggregate of 110,024,634 number of equity shares of the Company representing approximately 71.5% of the voting share capital of the Company. Consequent to the above, the Company has become a subsidiary of MP Laboratories (Mauritius) Ltd and a step down subsidiary of Mylan Laboratories Inc. Mr. N. Prasad continues to be the Promoter of the Company and to hold around 5% of the paid-up share capital of the Company. Further, India Newbridge Investments Limited, India Newbridge Partners FDI Limited, India Newbridge Coinvestment Limited, Maxwell (Mauritius) Pte Limited have sold their entire shareholding to the Acquirers and shall not be the Promoters of the Company